The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy

HIV Medicine

Volumn 6, Issue 2, 2005, Pages 122-128

  Cardiello, Peter ^a,b,e   Srasuebkul, P ^a   Hassink, E ^a,b   Mahanontharit, A ^a   Samor, T ^a   Ruxrungtham, K ^a,c   Lange, J ^b   Cooper, D ^d   Phanuphak, P ^a,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

Boosted; Immune reconstitution; Once daily; Saquinavir

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ITRACONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; ORAL ANTIDIABETIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INDIGESTION; LACTIC ACIDOSIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; THROMBOCYTOPENIA; TONSILLITIS; VIRUS LOAD; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TRIGLYCERIDES; VIRAL LOAD;

EID: 15844390621     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00274.x     Document Type: Article

References (17)

1. Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2002; 288 222-235.
2. Maggiolo F, Migliorino M, Maserati R et al. [Once Study Group]. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001; 6: 249-253.
3. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17 2603-2614.
4. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-1019.
5. Gathe JC Jr, Ive P, Wood R et al. [SOLO]. 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-1537.
6. Lamotte C, Landman R, Peytavin G et al. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther 2004; 9 247-256.
7. Eron JJ, Feinberg J, Kessler HA et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189: 265-272.
8. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998; 55 461-486.
9. Veldkamp AI, van Heeswijk RP, Mulder JW et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27: 344-349.
10. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-113.
11. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997; 19 159-175.
12. Cardiello PG, van Heeswijk RP, Hassink EA et al. Simplifying protease inhibitor therapy with once daily dosing of saquinavir (soft gel)/ritonavir 1,600/100 mg: HIVNAT 001 3. J Acquir Immune Defic Syndr 2002; 29, 464-470.
13. Kroon ED, Ungsedhapand C, Ruxrungtham K et al. A randomized, double blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). AIDS 2000; 14: 1349-1356.
14. Cardiello PG, Samor T, Burger D et al. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Antivir Ther 2003; 8: 245-249.
15. Havlir DV, Bassett R, Levitan D et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. J Am Med Assoc 2001; 286: 224-226.
16. Cohen Stuart JW, Wensing AM, Kovacs C et al. Transient relapses ('blips') of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28: 105-113.
17. Reynolds JEF. Martindale: The Extra Pharmacopoiea, 28th edn. London, The Pharmaceutical Press, 1982.